Evidence map›Paper›PMID 31173819›Full record

ArticleExperimental hematology2019

Fetal hemoglobin and F-cell variance in mobilized CD34

Selami Demirci, Juan J Haro Mora, Morgan Yapundich, Claire Drysdale, Jackson Gamer, Tina Nassehi, Aylin C Bonifacino, Allen E Krouse, Nathaniel S Linde, Robert E Donahue and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Selami DemirciCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Juan J Haro MoraCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Morgan YapundichCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Claire DrysdaleCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Jackson GamerCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Tina NassehiCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Aylin C BonifacinoTranslational Stem Cell Biology Branch, National Heart Lung and Blood Institutes, National Institutes of Health, Bethesda, MD.
Allen E KrouseTranslational Stem Cell Biology Branch, National Heart Lung and Blood Institutes, National Institutes of Health, Bethesda, MD.
Nathaniel S LindeTranslational Stem Cell Biology Branch, National Heart Lung and Blood Institutes, National Institutes of Health, Bethesda, MD.
Robert E DonahueTranslational Stem Cell Biology Branch, National Heart Lung and Blood Institutes, National Institutes of Health, Bethesda, MD.
John F TisdaleCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. Electronic address: johntis@mail.nih.gov.
Naoya UchidaCellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
National Institute of Diabetes and Digestive and Kidney Diseases · USNational Heart Lung and Blood Institute · US

Funding

Retroviral Mediated Gene Transfer Into Primate Hematopoietic CellsZIAHL002338 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HONG, SO GUN · 2019 to 2025
$26.3M
Preclinical and Clinical Studies in Gene Therapy for Sickle Cell DiseaseZIAHL006008 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI TISDALE, JOHN · 2009 to 2025
$14.6M
A preclinical large animal model for globin gene transferZ01HL006008 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI TISDALE, JOHN · 2008 to 2008
$330k
Intramural NIH HHS Z01 HL006008
6 · The paper itself

Abstract

Elevated fetal hemoglobin (HbF) is associated with reduced severity of sickle cell disease. Therefore, γ-globin protein levels and F-cell (HbF-positive red blood cell) percentages are used for estimation of clinical benefit. Here, we monitored transplantation-related changes in HbF and F-cell percentages for rhesus macaques (Macaca mulatta) following total body irradiation or busulfan conditioning prior to CD34

Indexed as

Hematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationTransplantation ConditioningAllograftsAnemia, Sickle CellAnimalsAntigens, CD34BusulfanErythrocytes, AbnormalFetal HemoglobinMacaca mulattaWhole-Body IrradiationAntigens, CD34BusulfanFetal Hemoglobin

Identifiers

PMID31173819
PMCPMC8459570
OpenAlexW2948400279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.